{"classes":[{"categories":[{"measurements":[{"comment":"Upper confidence interval is not available due to insufficient number of events","groupId":"OG002","lowerLimit":"6.28","upperLimit":"NA","value":"8.18"},{"comment":"Median DFS is not available due to insufficient number of events","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"18"}],"units":"Participants"}],"description":"Will be compared between Arms A and B.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 and then pomalidomide PO QD beginning between days 21-30 for 14 days in the absence of disease progression or unacceptable toxicity. Patients who do not respond, may receive a second cycle of liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression and unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy and collection of blood samples throughout all phases of the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspiration and Biopsy: Undergo bone marrow aspirate and biopsy\n\nLiposome-encapsulated Daunorubicin-Cytarabine: Given IV\n\nPomalidomide: Given PO","id":"OG000","title":"Safety Run In DL1 (14 Days Pomalidomide)"},{"description":"Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 and then pomalidomide PO QD beginning between days 21-30 for 10 days in the absence of disease progression or unacceptable toxicity. Patients who do not respond, may receive a second cycle of liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression and unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy and collection of blood samples throughout all phases of the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspiration and Biopsy: Undergo bone marrow aspirate and biopsy\n\nLiposome-encapsulated Daunorubicin-Cytarabine: Given IV\n\nPomalidomide: Given PO","id":"OG001","title":"Safety Run In DL-1 (10 Days Pomalidomide)"},{"description":"INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 and then pomalidomide PO QD beginning between days 21-30 for 14 days in the absence of disease progression or unacceptable toxicity. Patients who do not respond, may receive a second cycle of liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression and unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy and collection of blood samples throughout all phases of the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspiration and Biopsy: Undergo bone marrow aspirate and biopsy\n\nLiposome-encapsulated Daunorubicin-Cytarabine: Given IV\n\nPomalidomide: Given PO","id":"OG002","title":"Arm A (Daunorubicin and Cytarabine Liposome, Pomalidomide)"},{"description":"INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients who do not respond, may receive a second cycle of liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression and unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy and collection of blood samples throughout all phases of the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspiration and Biopsy: Undergo bone marrow aspirate and biopsy\n\nLiposome-encapsulated Daunorubicin-Cytarabine: Given IV","id":"OG003","title":"Arm B (Daunorubicin and Cytarabine Liposome)"}],"paramType":"MEDIAN","populationDescription":"This outcome measure was not reported on for the safety run-in phase","reportingStatus":"POSTED","timeFrame":"From CR/CRi until relapse or death, assessed at 2 years","title":"Disease-free Survival (DFS)","type":"SECONDARY","unitOfMeasure":"months"}